---
	annotation-target: Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf
---



>%%
>```annotation-json
>{"created":"2022-07-23T16:10:51.369Z","updated":"2022-07-23T16:10:51.369Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":4071,"end":4342},{"type":"TextQuoteSelector","exact":"Standard-care second-line treat-ment  in  the  curative  setting  for  patients  with  relapsed  or  refractory  large  B-cell  lymphoma  is  high-dose  chemotherapy  with  au-tologous stem-cell transplantation if the disease is responsive to salvage chemoimmunotherapy.1","prefix":"for  L a rge  B- Cell  Lymphom a","suffix":"-3 Certain disease characteristi"}]}]}
>```
>%%
>*%%PREFIX%%for  L a rge  B- Cell  Lymphom a%%HIGHLIGHT%% ==Standard-care second-line treat-ment  in  the  curative  setting  for  patients  with  relapsed  or  refractory  large  B-cell  lymphoma  is  high-dose  chemotherapy  with  au-tologous stem-cell transplantation if the disease is responsive to salvage chemoimmunotherapy.1== %%POSTFIX%%-3 Certain disease characteristi*
>%%LINK%%[[#^4ou16fx5dh4|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^4ou16fx5dh4


>%%
>```annotation-json
>{"created":"2022-07-23T16:11:06.471Z","updated":"2022-07-23T16:11:06.471Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":4637,"end":4859},{"type":"TextQuoteSelector","exact":"Patients whose disease does not respond to salvage chemother-apy  and  those  who  are  not  considered  to  be  candidates  for  high-dose  chemotherapy  with  autologous  stem-cell  transplantation  have  poor  outcomes.","prefix":" the likelihood of response.4,5 ","suffix":"4,6,7  These  patients  may  ben"}]}]}
>```
>%%
>*%%PREFIX%%the likelihood of response.4,5%%HIGHLIGHT%% ==Patients whose disease does not respond to salvage chemother-apy  and  those  who  are  not  considered  to  be  candidates  for  high-dose  chemotherapy  with  autologous  stem-cell  transplantation  have  poor  outcomes.== %%POSTFIX%%4,6,7  These  patients  may  ben*
>%%LINK%%[[#^vnroae3q3k|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^vnroae3q3k


>%%
>```annotation-json
>{"created":"2022-07-23T16:12:12.443Z","updated":"2022-07-23T16:12:12.443Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":4967,"end":5234},{"type":"TextQuoteSelector","exact":"The  autologous  anti-CD19  chimeric  antigen  receptor (CAR) T-cell therapy axicabtagene cilo-leucel (axi-cel) is approved for the treatment of patients with relapsed or refractory large B-cell lymphoma who have received at least two previ-ous  systemic  therapies.8","prefix":"different mecha-nisms of action.","suffix":",9  In  the  ZUMA-1  trial,  whi"}]}]}
>```
>%%
>*%%PREFIX%%different mecha-nisms of action.%%HIGHLIGHT%% ==The  autologous  anti-CD19  chimeric  antigen  receptor (CAR) T-cell therapy axicabtagene cilo-leucel (axi-cel) is approved for the treatment of patients with relapsed or refractory large B-cell lymphoma who have received at least two previ-ous  systemic  therapies.8== %%POSTFIX%%,9  In  the  ZUMA-1  trial,  whi*
>%%LINK%%[[#^ii1d0p7u3fk|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^ii1d0p7u3fk


>%%
>```annotation-json
>{"created":"2022-07-23T16:17:03.726Z","updated":"2022-07-23T16:17:03.726Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":7744,"end":7820},{"type":"TextQuoteSelector","exact":"Randomization was stratified according to response  to  first-line  therapy ","prefix":"dard-care  chemoimmunother-apy. ","suffix":" (refractory  vs.  re-lapsed dis"}]}]}
>```
>%%
>*%%PREFIX%%dard-care  chemoimmunother-apy.%%HIGHLIGHT%% ==Randomization was stratified according to response  to  first-line  therapy== %%POSTFIX%%(refractory  vs.  re-lapsed dis*
>%%LINK%%[[#^8ikhztd5aia|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^8ikhztd5aia


>%%
>```annotation-json
>{"created":"2022-07-23T16:17:12.820Z","updated":"2022-07-23T16:17:12.820Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":7858,"end":7894},{"type":"TextQuoteSelector","exact":"and the second-line age-adjusted IPI","prefix":"actory  vs.  re-lapsed disease) ","suffix":" (0 or 1 risk factor [indicating"}]}]}
>```
>%%
>*%%PREFIX%%actory  vs.  re-lapsed disease)%%HIGHLIGHT%% ==and the second-line age-adjusted IPI== %%POSTFIX%%(0 or 1 risk factor [indicating*
>%%LINK%%[[#^54ldqwwuglg|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^54ldqwwuglg


>%%
>```annotation-json
>{"created":"2022-07-23T16:21:21.354Z","text":"Procedimento que separa células brancas do resto do sangue, sem tirar o resto do sangue do paciente.","updated":"2022-07-23T16:21:21.354Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":8004,"end":8063},{"type":"TextQuoteSelector","exact":"Patients  in  the  axi-cel  group  underwent  leukapheresis","prefix":"ctors [indicating high risk]).  ","suffix":", followed by conditioning chemo"}]}]}
>```
>%%
>*%%PREFIX%%ctors [indicating high risk]).%%HIGHLIGHT%% ==Patients  in  the  axi-cel  group  underwent  leukapheresis== %%POSTFIX%%, followed by conditioning chemo*
>%%LINK%%[[#^3zjdpgi72va|show annotation]]
>%%COMMENT%%
>Procedimento que separa células brancas do resto do sangue, sem tirar o resto do sangue do paciente.
>%%TAGS%%
>#Técnica
^3zjdpgi72va


>%%
>```annotation-json
>{"created":"2022-07-24T01:12:58.212Z","text":"Teve dias anteriores a contagem com quimioterapia","updated":"2022-07-24T01:12:58.212Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":8065,"end":8387},{"type":"TextQuoteSelector","exact":"followed by conditioning chemo-therapy  with  cyclophosphamide  (at  a  dose  of  500  mg  per  square  meter  of  body-surface  area  per day) and fludarabine (30 mg per square meter per day) at −5, −4, and −3 days before receiving a single infusion of axi-cel (target dose, 2×106 CAR T cells per kilogram of body weight)","prefix":"roup  underwent  leukapheresis, ","suffix":". Op-tional bridging therapy was"}]}]}
>```
>%%
>*%%PREFIX%%roup  underwent  leukapheresis,%%HIGHLIGHT%% ==followed by conditioning chemo-therapy  with  cyclophosphamide  (at  a  dose  of  500  mg  per  square  meter  of  body-surface  area  per day) and fludarabine (30 mg per square meter per day) at −5, −4, and −3 days before receiving a single infusion of axi-cel (target dose, 2×106 CAR T cells per kilogram of body weight)== %%POSTFIX%%. Op-tional bridging therapy was*
>%%LINK%%[[#^9m2elg2f4g|show annotation]]
>%%COMMENT%%
>Teve dias anteriores a contagem com quimioterapia
>%%TAGS%%
>
^9m2elg2f4g


>%%
>```annotation-json
>{"created":"2022-07-24T01:15:05.762Z","updated":"2022-07-24T01:15:05.762Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":8454,"end":8600},{"type":"TextQuoteSelector","exact":"Patients in the standard-care group received two or three cycles of protocol-defined, investigator-selected,  platinum-based  chemoim-munotherapy.","prefix":"mited to glucocor-ticoids only. ","suffix":"  Patients  who  had  a  complet"}]}]}
>```
>%%
>*%%PREFIX%%mited to glucocor-ticoids only.%%HIGHLIGHT%% ==Patients in the standard-care group received two or three cycles of protocol-defined, investigator-selected,  platinum-based  chemoim-munotherapy.== %%POSTFIX%%Patients  who  had  a  complet*
>%%LINK%%[[#^3t9pkn99udr|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^3t9pkn99udr


>%%
>```annotation-json
>{"created":"2022-07-24T01:22:35.281Z","text":"Síndrome de liberação de [[Citocina|citocinas]] é uma síndrome inflamatória aguda sistêmica que causa febre e disfunção múltipla de órgãos (comum em leucemia linfoblástica aguda de células B).","updated":"2022-07-24T01:22:35.281Z","document":{"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","link":[{"href":"urn:x-pdf:421d54a7a96eb8d6ad0ddb529be4c25d"},{"href":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf"}],"documentFingerprint":"421d54a7a96eb8d6ad0ddb529be4c25d"},"uri":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","target":[{"source":"vault:/P2/Gen%C3%A9tica M%C3%A9dica/Trabalho U3/Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.pdf","selector":[{"type":"TextPositionSelector","start":9461,"end":9488},{"type":"TextQuoteSelector","exact":"cytokine  release  syndrome","prefix":"UMA-1.13 The severity  of  the  ","suffix":"  was  graded according to the m"}]}]}
>```
>%%
>*%%PREFIX%%UMA-1.13 The severity  of  the%%HIGHLIGHT%% ==cytokine  release  syndrome== %%POSTFIX%%was  graded according to the m*
>%%LINK%%[[#^2l633zko7u4|show annotation]]
>%%COMMENT%%
>Síndrome de liberação de [[Citocina|citocinas]] é uma síndrome inflamatória aguda sistêmica que causa febre e disfunção múltipla de órgãos (comum em leucemia linfoblástica aguda de células B).
>%%TAGS%%
>#Importante
^2l633zko7u4
